Skye Bioscience, Inc. Stock Other OTC
Equities
SKYE
US83086J1016
Biotechnology & Medical Research
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 154M |
---|---|---|---|---|---|
Net income 2024 * | -24M | Net income 2025 * | -33M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-5.81
x | P/E ratio 2025 * |
-5.21
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.81% |
Managers | Title | Age | Since |
---|---|---|---|
Punit Dhillon
CEO | Chief Executive Officer | 44 | 18-01-18 |
Director of Finance/CFO | - | 21-10-04 | |
Chief Tech/Sci/R&D Officer | 52 | 22-12-12 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 77 | 20-08-06 | |
Praveen Tyle
BRD | Director/Board Member | 64 | 21-07-21 |
Andrew Schwab
BRD | Director/Board Member | 53 | 23-08-17 |
1st Jan change | Capi. | |
---|---|---|
+18.97% | 45.34B | |
+41.98% | 40.42B | |
-10.06% | 37.92B | |
+31.15% | 31.75B | |
-7.79% | 27.71B | |
+13.32% | 26.52B | |
+43.05% | 13.96B | |
+31.28% | 12.44B | |
-7.41% | 11.26B |